COMMUNIQUÉS West-GlobeNewswire

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
15/05/2025
KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today [...]
Best Delta 8 Gummies For Euphoria by Candy Cloud in 2025
15/05/2025
LOS ANGELES, May 15, 2025 (GLOBE NEWSWIRE) -- Search interest for Delta-8 THC has grown over 800% since 2020, and gummies dominate those queries. According to Google Trends and retail data, gummies now outpace [...]
Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions
15/05/2025
Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration BRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) [...]
L'auto-injecteur sans aiguille ZENEO® de CROSSJECT est conforme aux profondeurs des injections intramusculaires traditionnelles et surpasse les longueurs des aiguilles des auto-injecteurs actuels
15/05/2025
Communiqué de Presse L'auto-injecteur sans aiguille ZENEO® de CROSSJECT est conforme aux profondeurs des injections intramusculaires traditionnelles et surpasse les longueurs des aiguilles des auto-injecteurs actuels La [...]
CROSSJECT’s ZENEO® needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors
15/05/2025
Press Release CROSSJECT’s ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors Injection depth [...]
AB Science annonce aujourd'hui une nouvelle publication dans la revue scientifique PLOS One, montrant l’effet neuroprotecteur prometteur du masitinib
15/05/2025
COMMUNIQUÉ DE PRESSE LE MASITINIB MONTRE DES EFFETS NEUROPROTECTEURS PROMETTEURS DANS UN MODÈLE DE MALADIE NEURODÉGÉNÉRATIVE INDUITE PAR LE SYSTÈME IMMUNITAIRE UNE NOUVELLE PUBLICATION DANS LA REVUE SCIENTIFIQUE PLOS [...]
AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib
15/05/2025
PRESS RELEASE MASITINIB SHOWS PROMISING NEUROPROTECTIVE EFFECTS IN NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE MODEL A NEW PUBLICATION IN THE SCIENTIFIC JOURNAL PLOS ONE, SHOWS THAT MASITINIB CAN LOWER SERUM [...]
Aino Health AB (publ): interim report january-march 2025
15/05/2025
This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail. Increased turnover. Positive cashflow. Positive EBITDA. January – March 2024 Turnover [...]
Audien Atom Hearing Aid Under Review: The Audien Pro & Atom One OTC Hearing Devices for Crystal Clear Sound
15/05/2025
Exploring how Audien's OTC hearing aids—Atom One and Pro 2—are transforming hearing accessibility with invisible designs, crystal clear sound, and prescription-free convenience for adults with mild to moderate hearing [...]
NovaaLab Under Review: Best At-Home Red Light Therapy Products for Healing Pain & Recovery Support
15/05/2025
Explore NovaaLab’s FDA-cleared red light therapy devices, supported by clinical studies, and designed to help reduce pain, improve recovery, and support wellness — all from the comfort of home. Salt Lake City, May 14, [...]
FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
15/05/2025
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug [...]
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
14/05/2025
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late [...]
Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia
14/05/2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the [...]
BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
14/05/2025
MELVILLE, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and [...]
Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine
14/05/2025
Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding Machine learning analyses identified statistically significant correlates of protection and will be [...]
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
14/05/2025
SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and [...]
Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th
14/05/2025
MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance [...]
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights
14/05/2025
- Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD - Presented the first human data mapping cell-level [...]

Pages